Development of immunohistochemistry for detecting fluvoxamine in rat tissues using newly prepared monoclonal antibody: its precise localization in small intestine, kidney, and liver of rats.
Fluvoxamine
Immunohistochemistry
Kidney
Liver
Small intestine
Journal
Medical molecular morphology
ISSN: 1860-1499
Titre abrégé: Med Mol Morphol
Pays: Japan
ID NLM: 101239023
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
31
05
2022
accepted:
29
09
2022
pubmed:
12
10
2022
medline:
25
2
2023
entrez:
11
10
2022
Statut:
ppublish
Résumé
A monoclonal antibody (mAb) was produced against a fluvoxamine (FLV)-bovine serum albumin conjugate that was specific to both the conjugate and free form of FLV. The mAb enabled us to develop an immunohistochemistry (IHC) method for pharmacokinetic analysis of FLV at the cell and tissue levels. We demonstrated that IHC can be used to detect the localization of FLV in the small intestine, kidney, and liver 1 h after drug administration at the cell and tissue levels. Protease digestion is an important factor for obtaining appropriate IHC staining results for localization of drugs. In this study, precise FLV localization could be determined with only 1 h of protease digestion in the kidneys, but in the small intestine and liver, the staining results with two digestive conditions had to be merged. IHC provided new findings, such as (1) nerve cells are likely to uptake more FLV than other cells and tissues; (2) the ability of reabsorption and secretion in the kidney varies depending on the site, and the amount of FLV in the primary urine is regulated downstream of the proximal tubule S3 segment; and (3) some of the FLV is excreted in the bile.
Identifiants
pubmed: 36219258
doi: 10.1007/s00795-022-00337-6
pii: 10.1007/s00795-022-00337-6
pmc: PMC9552737
doi:
Substances chimiques
Fluvoxamine
O4L1XPO44W
Antibodies, Monoclonal
0
Peptide Hydrolases
EC 3.4.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
28-37Informations de copyright
© 2022. The Author(s) under exclusive licence to The Japanese Society for Clinical Molecular Morphology.
Références
World Health Organization (2017) Depression and other common mental disorders. global health estimates. https://apps.who.int/iris/bitstream/handle/10665/254610/WHO-MSD-MER-2017.2-eng.pdf?sequence=1&isAllowed=y
Ishikawa H, Kawakami N, Kessler RC, World mental health Japan survey collaborators (2016) Lifetime and 12-month prevalence, severity and unmet need for treatment of common mental disorders in Japan: results from the final dataset of world mental health Japan survey. Epidemiol Psychiatr Sci 25:217–229
doi: 10.1017/S2045796015000566
pubmed: 26148821
Nichi-Iko Pharmaceutical Co. Ltd (2021) Fluvoxamine maleate, interview form. https://www.info.pmda.go.jp/go/interview/1/530169_1179039F1168_1_015_1F.pdf
Anderson G, Maes M, Markus RP, Rodriguez M (2015) Ebola virus: melatonin as a readily available treatment option: ebola and melatonin. J Med Virol 87:537–543
doi: 10.1002/jmv.24130
pubmed: 25611054
Almási N, Török S, Dvorácskó S, Tömböly C, Csonka Á, Baráth Z, Murlasits Z, Valkusz Z, Pósa A, Varga C, Kupai K (2020) lessons on the sigma-1 receptor in TNBS-induced rat colitis: modulation of the UCHL-1, IL-6 pathway. Int J Mol Sci 21:4046
doi: 10.3390/ijms21114046
pubmed: 32516975
pmcid: 7312485
Hooper PL (2020) COVID-19 and heme oxygenase: novel insight into the disease and potential therapies. Cell Stress Chaperones 25:707–710
doi: 10.1007/s12192-020-01126-9
pubmed: 32500379
pmcid: 7271958
Hooper PL (2022) Heme oxygenase agonists-fluvoxamine, melatonin-are efficacious therapy for Covid-19. Cell Stress Chaprones 27:3–4
doi: 10.1007/s12192-021-01246-w
Facente SN, Reiersen AM, Lenze EJ, Boulware DR, Klausner JD (2021) Fluvoxamine for the early treatment of SARS-CoV-2 infection: a review of current evidence. Drugs 81:2081–2089
doi: 10.1007/s40265-021-01636-5
pubmed: 34851510
pmcid: 8633915
Lenze EJ, Mattar C, Zorumski CF, Stevens A, Schweiger J, Nicol GE, Miller JP, Yang L, Yingling M, Avidan MS, Reiersen AM (2020) Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. JAMA 324:2292
doi: 10.1001/jama.2020.22760
pubmed: 33180097
pmcid: 7662481
Reis G, Dos Santos Moreira-Silva EA, Silva DCM, Thabane L, Milagres AC, Ferreira TS, Dos Santos CVQ, de Souza Campos VH, Nogueira AMR, de Almeida APFG, Callegari ED, de Figueiredo Neto AD, Savassi LCM, Simplicio MIC, Ribeiro LB, Oliveira R, Harari O, Forrest JI, Ruton H, Sprague S, McKay P, Glushchenko AV, Rayner CR, Lenze EJ, Reiersen AM, Guyatt GH, Mills EJ, TOGETHER Investigators (2022) Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the together randomised, platform clinical trial. Lancet Glob Health 10:e42–e51
doi: 10.1016/S2214-109X(21)00448-4
pubmed: 34717820
Fujiwara K, Yasuno M, Kitagawa T (1981) Novel preparation method of immunogen for hydrophobic hapten, enzyme immunoassay for daunomycin and adriamycin. J Immunol METHODS 45:195–203
doi: 10.1016/0022-1759(81)90213-1
pubmed: 7026686
Fujiwara K, Yasuno M, Kitagawa T (1981) Distribution of anticancer antibiotic daunomycin in the rat heart and kidney revealed by immunocytochemistry using monoclonal antibodies. Histochem Cell Biol 127:69–77
doi: 10.1007/s00418-006-0216-z
Fujiwara K, Shin M, Hougaard DM, Larsson L-I (2007) Distribution of anticancer antibiotic daunomycin in the rat heart and kidney revealed by immunocytochemistry using monoclonal antibodies. Histochem Cell Biol 127:69–77
doi: 10.1007/s00418-006-0216-z
pubmed: 16850318
Yamamoto Y, Yamamoto Y, Saita T, Shin M (2015) immunohistochemistry for anti-diabetes drug, alogliptin using a newly prepared monoclonal antibody: its precise localization in rat small intestine. Acta Histochem Cytochem 52:27–34
doi: 10.1267/ahc.18036
Fujiwara K, Yoshizaki Y, Shin M, Miyazaki T, Saita T, Nagata S (2012) immunocytochemistry for vancomycin using a monoclonal antibody that reveals accumulation of the drug in rat kidney and liver. Antimicrob Agents Chemother 56:5883–5891
doi: 10.1128/AAC.01267-12
pubmed: 22948874
pmcid: 3486582
Yamamoto Y, Yamamoto Y, Saita T, Hira D, Chijiwa T, Shin M (2020) Immunohistochemical pharmacokinetics of the anti-diabetes drug alogliptin in rat kidney and liver. Acta Histochem Cytochem 53:55–60
doi: 10.1267/ahc.19036
pubmed: 32624630
pmcid: 7322161
Yamamoto Y, Yamamoto Y, Saita T, Shin M (2021) Immunohistochemical localization and pharmacokinetics of the anti-MRSA drug teicoplanin in rat kidney using a newly developed specific antibody. Med Mol Morphol 54:227–236
doi: 10.1007/s00795-021-00286-6
pubmed: 33864519
Finley JC, Grossman GH, Dimeo P, Petrusz P (1978) Somatostatin-containing neurons in the rat brain: widespread distribution revealed by immunocytochemistry after pretreatment with pronase. Am J Anat 153:483–488
doi: 10.1002/aja.1001530312
pubmed: 360818
Clancy B, Cauller LJ (1998) Reduction of background autofluorescence in brain sections following immersion in sodium borohydride. J Neurosci Methods 83:97–102
doi: 10.1016/S0165-0270(98)00066-1
pubmed: 9765122
Haraguchi CM, Yokota S (2002) Immunofluorescence technique for 100-nm-thick semithin sections of Epon-embedded tissues. Histochem Cell Biol 117:81–85
doi: 10.1007/s00418-001-0363-1
pubmed: 11819100
Fujiwara K, Shin M, Miyazaki T, Maruta Y (2011) Immunocytochemistry for amoxicillin and its use for studying uptake of the drug in the intestine, liver, and kidney of rats. Antimicrob Agents Chemother 55:62–71
doi: 10.1128/AAC.01031-10
pubmed: 20974868
Madsen KM, Tisher CC (1986) Structural-functional relationship along the distal nephron. Am J Physiol 250:F1–F15
pubmed: 3521338